US FDA extends review of Novo Nordisk's hemophilia drug over facility issues

The FDA extended its review of Novo Nordisk's experimental hemophilia A treatment because remediation work remains ongoing at a manufacturing facility. The delay creates additional regulatory and manufacturing uncertainty for the drug's potential approval timeline, posing a modest near-term negative for Novo Nordisk.